Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 1/2

NCT05010122

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute My…

This phase I/II trial studies the best dose of gilteritinib given together with ASTX727 and venetoclax and the effect of ASTX727, venetoclax, and gilteritinib i…

United States42 participantsStarted 2021-07-08

Treatment: Decitabine and Cedazuridine, Gilteritinib

All recent trials (8 shown)

CompletedPhase 3

NCT03250338

Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

This is a randomized, multi-center, double-blind, placebo-controlled study designed to evaluate the efficacy of crenolanib administered following salvage chemot…

United States106 participantsStarted 2018-08-16

Treatment: Crenolanib, Cytarabine

CompletedPhase 2

NCT01522469

Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations

This is a Phase II open label study of crenolanib besylate. This study will enroll subjects with relapsed or refractory AML with FLT3 activating mutations. Prio…

United States14 participantsStarted 2012-07

Treatment: Crenolanib Besylate (CP-868,596-26)

Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute My…

All recent trials (8 shown)

Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute My…

All recent trials (8 shown)

Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations

A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations

A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies

Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and…

Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)

Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation